Send to:

Choose Destination
See comment in PubMed Commons below
Thrombosis. 2011;2011:530183. doi: 10.1155/2011/530183. Epub 2011 Apr 12.

Clinical use of the low-molecular-weight heparins in cancer patients: focus on the improved patient outcomes.

Author information

  • 1Department of Medicine, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, Madison WI 53792, USA.


Patients with malignant neoplastic diseases represent a high-risk population relative to thromboembolic disease. With the advent of improved and accessible diagnostic technology, for example, ultrasound and/or spiral CT scans, timely diagnosis of venous thromboembolic events (VTE) is readily accomplished. The introduction of low-molecular-weight heparin (LMWH) approximately two decades ago (in contrast to unfractionated heparin and vitamin K antagonists) has provided a class of agents with a favorable therapeutic index. In the review to follow, the literature regarding the use of LMWH in oncologic patient populations is summarized. Topics addressed include prophylaxis, and treatment as well as consideration of the potential anti-neoplastic properties of this class of drugs.

Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk